Project Grant R01CA289885
Award Date 6/20/26
Completion Date 5/31/31
Dollars Obligated $597K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $339,736 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. (DFCI) on May 7, 2025, with completion anticipated by April 30, 2030. This award supports research aimed at resolving diagnostic and phenotypic challenges in translocation renal cell carcinoma (TRCC), a rare and aggressive cancer subtype that is frequently misdiagnosed due to phenotypic overlap with...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $131,933 Project Grant to The University of Texas MD Anderson Cancer Center under the Cancer Research Manpower program (CFDA 93.398) for the period May 1, 2026 through April 30, 2028. This award supports research focused on spatial and functional profiling of tumor evolution trajectories and microenvironment interactions in VHL-driven renal cancers, specifically clear cell renal cell carcinoma (CCRC). The...
- Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas MD Anderson Cancer Center a $473,372 Project Grant under the Cancer Biology Research program (CFDA 93.396) to investigate proline tRNA (transfer RNA) biogenesis as an oncogenic driver and therapeutic target in T cell acute lymphoblastic leukemia (T-ALL). The research, which commenced April 8, 2026, and extends through March 31, 2031, will characterize the molecular mechanisms by which upregulated...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 project grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025 and concluding August 31, 2027. This grant funds research investigating P300/CBP (lysine acetyltransferases) as novel therapeutic targets in clear cell renal cell carcinoma (ccRCC). The research will examine the therapeutic potential of targeting P300/CBP through pharmacological...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Project Grant Summary The National Cancer Institute awarded $528,902 to The University of Texas Southwestern Medical Center on September 12, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a five-year research project examining genomic correlates of outcome in pleuropulmonary blastoma (PPB). The project focuses on understanding how different DICER1 gene variants affect clinical prognosis, microRNA production, and tumor behavior in pediatric lung...
- Federal Grant Award Summary The National Cancer Institute awarded a $404,972 Project Grant to The University of Texas Health Science Center at San Antonio under the Cancer Biology Research program (CFDA 93.396) for a two-year project period beginning August 1, 2025 and concluding July 31, 2027. This award supports fundamental research investigating ribosomal ribonucleic acid (rRNA) modification, ribosome composition, and specialized translation mechanisms in glioblastoma, the most common and...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $530,106 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded September 11, 2025, with completion targeted for August 31, 2030. The award supports fundamental research to identify and mechanistically interrogate polyamine metabolism in leukemia stem cells (LSCs) as a therapeutic target for acute myeloid leukemia (AML) patients. The research...
- The National Cancer Institute awarded a $850,611 Cooperative Agreement to The University of Texas Southwestern Medical Center under the Cancer Biology Research program (CFDA 93.396) for a five-year project period beginning August 1, 2025 and concluding July 31, 2030. This award supports fundamental research investigating the regulation of mitochondrial activity and metastasis in renal cell carcinoma through examination of dihydrouridine modifications in transfer ribonucleic acids (tRNAs). The...